“We are committed to fast-tracking innovation and transformative care to patients”
BioSpectrum Asia|October 2020
Thomas Willemsen, Senior Vice President, Takeda Pharmaceuticals, APAC, Singapore
Hithaishi C Bhaska

The present pandemic scenarios are continuing to place immense pressure on healthcare systems across Asia Pacific (APAC). Rapidly growing, aging population and surging healthcare costs, making it challenging for governments to ensure citizens receive affordable, high-quality treatment and care. There is a need to act swiftly to alleviate these challenges to prevent prolonged stress on the healthcare systems by enhancing the healthcare sustainability. Amidst the severe burden on healthcare systems, global pharmaceutical companies like Takeda are expressing confidence to potentially transform the lives through their breakthrough innovative vaccines and medications. Takeda is focusing on value-based healthcare to deliver personalized, precise treatments aimed at improving patient outcomes, while ultimately lowering costs, to better invest in innovation and deliver impactful value to patients. Thomas Willemsen, Senior Vice President of Takeda Pharmaceuticals, APAC, Singapore has more to share on the Asia Pacific healthcare challenges and Takeda’s upcoming ventures, especially in combating dengue and COVID-19.

Edited excerpts;

Takeda is committed towards accelerating access to innovative medicines? Can you provide more insight on this?

Our Access to Medicines (AtM) initiative is about radically increasing access to innovative medicines for complex and rare diseases by mobilizing collective action to drive impact to patients. This is done through targeted partnerships that strengthen healthcare systems in a sustainable way, at every stage of the patient journey.

Through our AtM programme, we have equipped healthcare providers with diagnostic and treatment training across our therapeutic areas, and also developed collaborative financing models to ensure patients can complete their course of treatment, even when they cannot afford to pay in full. Since Takeda established these Patient Assistance Programmes in 2016, we have impacted the lives of close to 700 patients across APAC.

We are focused on long-term commitments and seek to shape the environment in these countries so that in the long-term, a sustainable reimbursement landscape that also covers complex and rare medical conditions may be possible.

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM BIOSPECTRUM ASIAView All

“We plan to launch our prevention and early detection service in India”

London headquartered Medix Global, a provider of innovative, high quality, medical management solutions, is gradually expanding its business in Asia. With its recent entry into India, the company is geared to provide access of its global healthcare services to Indian customers. It has strong credentials for providing customers with fast-tracked and personalized medical solutions, from the right diagnosis to optimized treatment pathways. BioSpectrum Asia spoke to Sigal Atzmon, Founder and CEO, Medix Global, London, UK to find out more about the company’s growth plans in Asia.

5 mins read
BioSpectrum Asia
January 2021

“We are planning to launch a new bioprocess controller in Q1 2021”

Bioprocess engineers develop and produce a multitude of products and ingredients available today. Their applications are diverse, and the products can be found in pharmaceutical, chemical, and nutrition industries. With an integrated portfolio comprising software, instruments, consumables, and services, Eppendorf can satisfy the demands of bioprocess development through production. To find out about what major is in store at Eppendorf Bioprocess, BioSpectrum spoke to Richard Mirro, Business Manager, Bioprocess at Eppendorf, Inc., US.

4 mins read
BioSpectrum Asia
January 2021

“We are confident that Sputnik V will be providing long-term immunization defence against potential new coronavirus infections”

On December 14, 2020, Moscow’s National Research Center for Epidemiology and Microbiology named ‘Gamaleya Center’ and the Russian Direct Investment Fund (RDIF) announced the efficacy of over 90 per cent of the Russian Sputnik V vaccine in Phase III post-registration clinical trials. RDIF joins partners and manufacturers in ramping up the production of Sputnik V. First batch of 300,000 doses of Sputnik V vaccine has already been delivered to Argentina by RDIF on December 24, 2020. In an interview with BioSpectrum Asia Kirill Dmitriev, CEO, Russian Direct Investment Fund (RDIF), Russia shared more insight on the encouraging efficacy data of the Sputnik V with Biospectrum Asia.

4 mins read
BioSpectrum Asia
January 2021

“Australia has reinforced its standing as a world-class destination for early phase clinical development”

Avance Clinical, a leading Australian Contract Research Organization (CRO) for biotech firms, and winner of the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award, has recently partnered with Europe’s leading CRO, Cromos Pharma. The collaboration will allow biotech firms to quickly start their pre-IND early phase studies in Australia, thereafter, expanding to Central/Eastern Europe to access the large patient populations for their Phase II and III studies. In an email interaction with BioSpectrum, Yvonne Lungershausen, CEO, Avance Clinical, Australia spoke about the Australian CRO market, and the impact of COVID-19 crisis.

4 mins read
BioSpectrum Asia
January 2021

Evaluating COVID-19 vaccines on mutant viral strains

While the viral variants and vaccine trials are contesting with each other, Norway based Coalition for Epidemic Preparedness Innovations (CEPI) has launched a first-of-its-kind collaboration to tackle emergence of new COVID-19 viral strains and evaluate their impact on vaccine candidates in development. Tracking viral mutations and diversity is essential to ensure efficacy of COVID-19 vaccine candidates on mutant virulent strains.

5 mins read
BioSpectrum Asia
January 2021

Taiwan initiates new measures for management of medical masks

Taiwan has initiated two new measures to reinforce the management of medical masks.

1 min read
BioSpectrum Asia
January 2021

Singapore gives nod to Pfizer-BioNTech COVID-19 vaccine

The Health Sciences Authority (HSA) has granted an authorization under the Pandemic Special Access Route (PSAR) for the Pfizer-BioNTech COVID-19 vaccine to be used in Singapore for the prevention of COVID-19.

1 min read
BioSpectrum Asia
January 2021

HiMedia gets multiple nods for COVID-19 products

HiGenoMB, the molecular biology division of Indian firm HiMedia Laboratories has received the CE/IVD approval and a nod from the Indian Council of Medical Research (ICMR) for its COVID-19 range of products.

1 min read
BioSpectrum Asia
January 2021

EuBiologics partners with IVI for COVID-19 vaccine development

The International Vaccine Institute (IVI) and South Korean company EuBiologics have exchanged a Memorandum of Understanding (MoU) to cooperate in the clinical development of the COVID-19 vaccine the company is currently developing.

1 min read
BioSpectrum Asia
January 2021

2021 beckons MAJOR investments IN R&D

The life sciences industry in Asia Pacific (APAC) region entered the year 2020 with companies entering into new agreements for expansion and focusing on applied research to develop new drugs that are affordable. During 2020, the industry, which acted timely, as covered in the January 2020 issue of BioSpectrum Asia, witnessed unprecedented collaborations with the governments due to the unexpected spread of coronavirus since December 2019. COVID-19 is expected to remain a defining issue for the life sciences industry across the globe in 2021, compelling companies to invest heavily in research and development.

6 mins read
BioSpectrum Asia
January 2021
RELATED STORIES

Zika Is the Next Front in the Mosquito Wars

 Based on damage from malaria and dengue, the spread of Zika will prove costly.

5 mins read
Bloomberg Businessweek
February 8 - February 14, 2016

Trusted Solutions

Trust is the cornerstone of secure access leader Dormakaba. For senior Vice President operations APAC oliver riess, this extends beyond solutions to the culture of the company itself.

7 mins read
The CEO Magazine Asia
January - February 2021

MANAGEMENT OF CO-INFECTION OF COVID-19 WITH OTHER SEASONAL EPIDEMIC PRONE DISEASES

Almost all States/UTs of the country are affected by COVID-19. Given the seasonal pattern of epidemic-prone diseases observed every year in our country, it diseases like Dengue, Malaria, Seasonal Influenza, Leptospirosis, Chikungunya, Enteric fever, etc. can not only present as a diagnostic dilemma but may co-exist in COVID cases.

10+ mins read
Future Medicine India
December 2020

Korn Ferry's Gareth McIlroy on jobs, skills, and changing workplace dynamics

For years organizations have been talking about digital transformation, but the pandemic has grabbed the concept and made it an absolute imperative for survival, says Gareth Mcilroy, Managing Director, Korn Ferry, Singapore, in an interaction with People Matters

7 mins read
People Matters
November 2020

Dairy: A New Era of Innovation

Although most countries produce milk products, the structure of the dairy industry differs across the globe. Many major dairy-producing countries consume most of their output internally, while others (for example New Zealand) export a large percentage of their production. Local consumption is often in the form of liquid milk, while the bulk of international trade is in processed dairy products such as milk powder.

6 mins read
Food Marketing & Technology - India
November 2020

Stop the Fall

Worried about your falling hair? Dr. Shefali Trasi Nerurkar - MD Skin, Consultant Dermatologist at Dr. Trasi’s Clinic & La Piel details the underlying causes of hairfall and hairloss to help you tackle this common haircare problem.

4 mins read
Beauty Launchpad India
October 2020

डेंगू विरोधी अभियान के कारण इस साल भी नहीं हुई डेंगू से कोई मौत : केजरीवाल

दिल्ली के लोगों से अभियान में शामिल होने की अपील

1 min read
Haribhoomi Delhi
November 01, 2020

Regina Lim Makes A Case For The Physical

In a time where everyone is going virtual, Regina Lim, head of capital markets research, APAC at JLL, makes a case for the physical.

5 mins read
PORTFOLIO Magazine
October 2020

डेंगू अभियान में जुटे बच्चे, सीएम ने सराहा

केजरीवाल ने अपने घर में रुके हुए साफ पानी को बदला

1 min read
Haribhoomi Delhi
October 05, 2020

कोरोना व डेंगू से पीड़ित डिप्टी सीएम सिसोदिया को दी गई प्लाज्मा थेरेपी

कोविड-19 : एलएनजेपी अस्पताल से मैक्स अस्पताल में किया शिफ्ट

1 min read
Haribhoomi Delhi
September 26, 2020